NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the Company has initiated an expanded access program at Massachusetts General Hospital (“MGH”) to provide its investigational drug, BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”), to critically ill patients diagnosed with COVID-19 in the intensive care unit ("ICU") that may require calming or arousable sedation. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Currently, Millendo does not offer EAPs for its product candidates. Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. All forward-looking statements are based upon BTI's current expectations and various assumptions. According to the FDA, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: firstname.lastname@example.org Website: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. The foregoing statements expressly qualify any forward-looking information contained herein. Any such forward-looking statements represent management’s estimates as of the date of this press release. Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation . BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time. Spectrum Therapeutics makes no representations and gives no warranties or conditions, whether express, implied, statutory, or otherwise, including, without limitation, any warranties or conditions of merchantability, merchantable quality, durability, or fitness for a particular purpose, all of which are hereby ... Compassionate pricing promise The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. “COVID-19 primarily affects the respiratory system, with the severely ill often requiring mechanical ventilation. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. TORONTO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate … This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. For you to receive an experimental drug through the compassionate use program, your doctor must contact the drug company and then submit an application to the FDA.For the FDA to consider your request, you must meet certain criteria:. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release. Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: email@example.comWebsite: www.revivethera.com. TORONTO, Sept. 16, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19 received approval from the independent Institutional Review Board (“IRB”).